Scroll for more

Product

 

AMITIZA®
(lubiprostone)

AMITIZA WITHIN THE
UNITED STATES

amitiza-us

 

Healthcare professionals, click here to learn more about AMITIZA and constipation.

Click here for full U.S. Prescribing Information for AMITIZA.

Click here for patient information for AMITIZA.

For more information or to report suspected adverse reactions related to AMITIZA, please call toll-free at 1-877-825-3327. Alternatively, you can report suspected adverse reactions directly to the FDA at www.FDA.gov/medwatch or call 1-800-FDA-1088.

 
 

The product websites presented here are intended for use in the United States only. There may be different regulations in other countries that may require referencing different information. If you require product information for a country other than the United States, please select a region below.

United States Asia Europe

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.